Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

Roth Capital analyst Boobalan Pachaiyappan has initiated coverage on Abeona Therapeutics (NASDAQ: ABEO) with a Buy rating. The firm has set a price target of $17 for the company's stock.